Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Protein Expr Purif ; 219: 106477, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38527576

ABSTRACT

Semaglutide is currently the most promising antidiabetic drug, especially for the treatment of type 2 diabetes mellitus, due to its excellent efficacy in glycemic control and weight loss. However, the production of semaglutide remains high cost, and high yield, low cost, and high purity still remains a challenge. Herein, we reported a convenient and high-yield strategy for the preparation of semaglutide through fragmented condensation coupling, involving solid-phase peptide synthesis of tetrapeptide and on-column refolding and on-column enzyme cleavage based inclusion body expression of Lys26Arg34GLP-1 (11-37) with fused protein tags in an X-Y-D4K-G pattern. The optimized N-terminal protein tag significantly boosts inclusion body expression level, while on-column refolding and on-column enzyme cleavage avoid precipitation, enhancing efficiency and yield together with one-step purification. The successful preparation of semaglutide is expected to achieve large-scale industrial production with low cost, high yield and high purity.


Subject(s)
Glucagon-Like Peptides , Inclusion Bodies , Solid-Phase Synthesis Techniques , Glucagon-Like Peptides/chemistry , Solid-Phase Synthesis Techniques/methods , Inclusion Bodies/chemistry , Escherichia coli/genetics , Escherichia coli/metabolism , Hypoglycemic Agents/chemistry , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...